Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
AIM 29 March 2019 NOTICE 29/03/2019 7:00am NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM - XLON At the request of the Company the following securities have been cancelled from trading on...
News) - Akers Biosciences Inc on Wednesday said that, at a meeting held on Tuesday, its shareholders approved the comp ...
Akers Biosciences, Inc. 06 March 2019 March 6, 2019 Akers Biosciences, Inc. Result of Special Meeting of Shareholders Cancellation of Admission of Common Stock to Trading on AIM Form 8-K Filing...
Akers Biosciences, Inc. 06 February 2019 February 6, 2019 Akers Biosciences, Inc. Holding in Company Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the...
Akers Biosciences, Inc. 06 February 2019 February 6, 2019 Akers Biosciences, Inc. Form DEFA14A Filing - Additional Proxy Soliciting Materials Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L...
Akers Biosciences, Inc. 06 February 2019 February 6, 2019 Akers Biosciences, Inc. Form DEF 14A Filing - Definitive Proxy Statement Notice of Special Meeting of Shareholders Proposed Cancellation...
Akers Biosciences, Inc. 05 February 2019 February 5, 2019 Akers Biosciences, Inc. Further Re. Directorate Change Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the...
Akers Biosciences, Inc. 28 January 2019 January 28, 2019 Akers Biosciences, Inc. Form PRE 14A Filing Filing of Preliminary Proxy Statement Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L...
Akers Biosciences, Inc. 28 December 2018 December 28, 2018 Akers Biosciences, Inc. Director/PDMR Shareholding Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or...
News) - Akers Biosciences Inc on Wednesday said it plans to leave London's AIM market, with most trading in its shares ...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
